


| | |
|--|---|
| MEDICAL POLICY | Genetic Testing: Gene Expression Profile Testing for Melanoma (Medicare Only) |
| Effective Date: 1/1/2022  1/1/2022 | Medical Policy Number: 253 Medical Policy Committee Approved Date: 7/19; 11/19; 7/2020; 9/2020; 12/2020; 9/2021; 11/2021 |
| Medical Officer | Date |

See Policy CPT CODE section below for any prior authorization requirements

SCOPE:

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Aycin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

APPLIES TO:

Medicare Only

| MEDICAL POLICY CRITERIA | |
|--|--|
| <p>The following Centers for Medicare & Medicaid Service (CMS) guidelines should be utilized for medical necessity coverage determinations. Click the link provided in the table below to access applicable medical necessity criteria. All listed guidelines apply.</p> | |
| Service | Medicare Guidelines |
| <i>Decision DX-UM (Uveal Melanoma) (81552; Castle Bioscience, Inc., Phoenix, AZ)</i> | Local Coverage Determination (LCD): Decision DX-UM (Uveal Melanoma) (L37072) |
| <i>Decision DX-Melanoma (81599; Castle Bioscience, Inc., Phoenix, AZ)</i> | <ul style="list-style-type: none"> • LCD: MoIDX: Melanoma Risk Stratification Molecular Testing (L37748) • Local Coverage Article(LCA): Billing and Coding: MoIDX: Melanoma Risk Stratification Molecular Testing (A57290) |
| <i>MyPath Melanoma Assay (0090U; Castle Biosciences, Inc.)</i> | LCD: MoIDX: myPath Melanoma Assay (L37881) |
| <i>Pigmented Lesion Assay (PLA; 0089U; DermTech, Inc., La Jolla, CA)</i> | LCD: MoIDX: Pigmented Lesion Assay (L38151) |

| | |
|-----------------------|--|
| MEDICAL POLICY | Genetic Testing: Gene Expression Profile Testing for Melanoma (Medicare Only) |
|-----------------------|--|

BILLING GUIDELINES

Please see the following LCAs for applicable billing guidelines:

- Billing and Coding: MoIDX: DecisionDx-UM (Uveal Melanoma) ([A57622](#))
- Billing and Coding for MoIDX: DecisionDX-Melanoma ([A56636](#))
- Billing and Coding: MoIDX: Melanoma Risk Stratification Molecular Testing ([A57290](#))
- Billing and Coding: MoIDX: myPath Melanoma Assay ([A57627](#))
- Billing and Coding: MoIDX: Pigmented Lesion Assay ([A58052](#))

CPT/HCPCS CODES

| Medicare Only | |
|--|--|
| Prior Authorization Required | |
| 0089U | Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es) |
| 0090U | Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant) |
| 81401 | Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat) |
| 81552 | Oncology (uveal melanoma), mRNA, gene expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis |
| 81529 | Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis |
| Unlisted Codes | |
| All unlisted codes will be reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is billed related to services addressed in this policy then prior-authorization is required. | |
| 81479 | Unlisted molecular pathology procedure |
| 81599 | Unlisted multianalyte assay with algorithmic analysis |
| 84999 | Unlisted chemistry procedure |

INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed

| | |
|-----------------------|--|
| MEDICAL POLICY | Genetic Testing: Gene Expression Profile Testing for Melanoma (Medicare Only) |
|-----------------------|--|

annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

REGULATORY STATUS

Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.